Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rachael E. Chicoine is active.

Publication


Featured researches published by Rachael E. Chicoine.


Cancer Epidemiology, Biomarkers & Prevention | 2014

Comparison of Mammographic Density Assessed as Volumes and Areas among Women Undergoing Diagnostic Image-Guided Breast Biopsy

Gretchen L. Gierach; Berta M. Geller; John A. Shepherd; Deesha A. Patel; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; Ruth M. Pfeiffer; Bo Fan; Amir Pasha Mahmoudzadeh; Jeff Wang; Jason M. Johnson; Sally D. Herschorn; Louise A. Brinton; Mark E. Sherman

Background: Mammographic density (MD), the area of non–fatty-appearing tissue divided by total breast area, is a strong breast cancer risk factor. Most MD analyses have used visual categorizations or computer-assisted quantification, which ignore breast thickness. We explored MD volume and area, using a volumetric approach previously validated as predictive of breast cancer risk, in relation to risk factors among women undergoing breast biopsy. Methods: Among 413 primarily white women, ages 40 to 65 years, undergoing diagnostic breast biopsies between 2007 and 2010 at an academic facility in Vermont, MD volume (cm3) was quantified in craniocaudal views of the breast contralateral to the biopsy target using a density phantom, whereas MD area (cm2) was measured on the same digital mammograms using thresholding software. Risk factor associations with continuous MD measurements were evaluated using linear regression. Results: Percent MD volume and area were correlated (r = 0.81) and strongly and inversely associated with age, body mass index (BMI), and menopause. Both measures were inversely associated with smoking and positively associated with breast biopsy history. Absolute MD measures were correlated (r = 0.46) and inversely related to age and menopause. Whereas absolute dense area was inversely associated with BMI, absolute dense volume was positively associated. Conclusions: Volume and area MD measures exhibit some overlap in risk factor associations, but divergence as well, particularly for BMI. Impact: Findings suggest that volume and area density measures differ in subsets of women; notably, among obese women, absolute density was higher with volumetric methods, suggesting that breast cancer risk assessments may vary for these techniques. Cancer Epidemiol Biomarkers Prev; 23(11); 2338–48. ©2014 AACR.


Cancer Prevention Research | 2016

Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities

Gretchen L. Gierach; Deesha A. Patel; Ruth M. Pfeiffer; Jonine D. Figueroa; Laura Linville; Daphne Papathomas; Jason M. Johnson; Rachael E. Chicoine; Sally D. Herschorn; John A. Shepherd; Jeff Wang; Serghei Malkov; Pamela M. Vacek; Donald L. Weaver; Bo Fan; Amir Pasha Mahmoudzadeh; Maya Palakal; Jackie Xiang; Hannah Oh; Hisani N. Horne; Brian L. Sprague; Stephen M. Hewitt; Louise A. Brinton; Mark E. Sherman

Elevated mammographic density (MD) is an established breast cancer risk factor. Reduced involution of terminal duct lobular units (TDLU), the histologic source of most breast cancers, has been associated with higher MD and breast cancer risk. We investigated relationships of TDLU involution with area and volumetric MD, measured throughout the breast and surrounding biopsy targets (perilesional). Three measures inversely related to TDLU involution (TDLU count/mm2, median TDLU span, median acini count/TDLU) assessed in benign diagnostic biopsies from 348 women, ages 40–65, were related to MD area (quantified with thresholding software) and volume (assessed with a density phantom) by analysis of covariance, stratified by menopausal status and adjusted for confounders. Among premenopausal women, TDLU count was directly associated with percent perilesional MD (P trend = 0.03), but not with absolute dense area/volume. Greater TDLU span was associated with elevated percent dense area/volume (P trend<0.05) and absolute perilesional MD (P = 0.003). Acini count was directly associated with absolute perilesional MD (P = 0.02). Greater TDLU involution (all metrics) was associated with increased nondense area/volume (P trend ≤ 0.04). Among postmenopausal women, TDLU measures were not significantly associated with MD. Among premenopausal women, reduced TDLU involution was associated with higher area and volumetric MD, particularly in perilesional parenchyma. Data indicating that TDLU involution and MD are correlated markers of breast cancer risk suggest that associations of MD with breast cancer may partly reflect amounts of at-risk epithelium. If confirmed, these results could suggest a prevention paradigm based on enhancing TDLU involution and monitoring efficacy by assessing MD reduction. Cancer Prev Res; 9(2); 149–58. ©2015 AACR.


Breast Cancer Research | 2016

Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease

Hisani N. Horne; Mark E. Sherman; Ruth M. Pfeiffer; Jonine D. Figueroa; Zeina G. Khodr; Roni T. Falk; Michael Pollak; Deesha A. Patel; Maya Palakal; Laura Linville; Daphne Papathomas; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; John A. Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Serghei Malkov; Sally D. Herschorn; Stephen M. Hewitt; Louise A. Brinton; Gretchen L. Gierach

BackgroundTerminal duct lobular units (TDLUs) are the primary structures from which breast cancers and their precursors arise. Decreased age-related TDLU involution and elevated mammographic density are both correlated and independently associated with increased breast cancer risk, suggesting that these characteristics of breast parenchyma might be linked to a common factor. Given data suggesting that increased circulating levels of insulin-like growth factors (IGFs) factors are related to reduced TDLU involution and increased mammographic density, we assessed these relationships using validated quantitative methods in a cross-sectional study of women with benign breast disease.MethodsSerum IGF-I, IGFBP-3 and IGF-I:IGFBP-3 molar ratios were measured in 228 women, ages 40-64, who underwent diagnostic breast biopsies yielding benign diagnoses at University of Vermont affiliated centers. Biopsies were assessed for three separate measures inversely related to TDLU involution: numbers of TDLUs per unit of tissue area (“TDLU count”), median TDLU diameter (“TDLU span”), and number of acini per TDLU (“acini count”). Regression models, stratified by menopausal status and adjusted for potential confounders, were used to assess the associations of TDLU count, median TDLU span and median acini count per TDLU with tertiles of circulating IGFs. Given that mammographic density is associated with both IGF levels and breast cancer risk, we also stratified these associations by mammographic density.ResultsHigher IGF-I levels among postmenopausal women and an elevated IGF-I:IGFBP-3 ratio among all women were associated with higher TDLU counts, a marker of decreased lobular involution (P-trend = 0.009 and <0.0001, respectively); these associations were strongest among women with elevated mammographic density (P-interaction <0.01). Circulating IGF levels were not significantly associated with TDLU span or acini count per TDLU.ConclusionsThese results suggest that elevated IGF levels may define a sub-group of women with high mammographic density and limited TDLU involution, two markers that have been related to increased breast cancer risk. If confirmed in prospective studies with cancer endpoints, these data may suggest that evaluation of IGF signaling and its downstream effects may have value for risk prediction and suggest strategies for breast cancer chemoprevention through inhibition of the IGF system.


Hormones and Cancer | 2015

Relationship of serum estrogens and metabolites with area and volume mammographic densities.

Gretchen L. Gierach; Deesha A. Patel; Roni T. Falk; Ruth M. Pfeiffer; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; John A. Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Sally D. Herschorn; Xia Xu; Timothy D. Veenstra; Barbara J. Fuhrman; Mark E. Sherman; Louise A. Brinton

Elevated mammographic density is a breast cancer risk factor, which has a suggestive, but unproven, relationship with increased exposure to sex steroid hormones. We examined associations of serum estrogens and estrogen metabolites with area and novel volume mammographic density measures among 187 women, ages 40–65, undergoing diagnostic breast biopsies at an academic facility in Vermont. Serum parent estrogens, estrone and estradiol, and their 2-, 4-, and 16-hydroxylated metabolites were measured using liquid chromatography-tandem mass spectrometry. Area mammographic density was measured in the breast contralateral to the biopsy using thresholding software; volume mammographic density was quantified using a density phantom. Linear regression was used to estimate associations of estrogens with mammographic densities, adjusted for age and body mass index, and stratified by menopausal status and menstrual cycle phase. Weak, positive associations between estrogens, estrogen metabolites, and mammographic density were observed, primarily among postmenopausal women. Among premenopausal luteal phase women, the 16-pathway metabolite estriol was associated with percent area (p = 0.04) and volume (p = 0.05) mammographic densities and absolute area (p = 0.02) and volume (p = 0.05) densities. Among postmenopausal women, levels of total estrogens, the sum of parent estrogens, and 2-, 4- and 16-hydroxylation pathway metabolites were positively associated with area density measures (percent: p = 0.03, p = 0.04, p = 0.01, p = 0.02, p = 0.07; absolute: p = 0.02, p = 0.02, p = 0.01, p = 0.02, p = 0.03, respectively) but not volume density measures. Our data suggest that serum estrogen profiles are weak determinants of mammographic density and that analysis of different density metrics may provide complementary information about relationships of estrogen exposure to breast tissue composition.


International Journal of Cancer | 2017

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast

Clara Bodelon; Hannah Oh; Nilanjan Chatterjee; Montserrat Garcia-Closas; Maya Palakal; Mark E. Sherman; Ruth M. Pfeiffer; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; Daphne Papathomas; Jackie Xiang; Deesha A. Patel; Zeina G. Khodr; Laura Linville; Susan E. Clare; Daniel W. Visscher; Carolyn Mies; Stephen M. Hewitt; Louise A. Brinton; Anna Maria Storniolo; Chunyan He; Stephen J. Chanock; Gretchen L. Gierach; Jonine D. Figueroa

Terminal duct lobular units (TDLUs) are the predominant source of future breast cancers, and lack of TDLU involution (higher TDLU counts, higher acini count per TDLU and the product of the two) is a breast cancer risk factor. Numerous breast cancer susceptibility single nucleotide polymorphisms (SNPs) have been identified, but whether they are associated with TDLU involution is unknown. In a pooled analysis of 872 women from two studies, we investigated 62 established breast cancer SNPs and relationships with TDLU involution. Poisson regression models with robust variance were used to calculate adjusted per‐allele relative risks (with the non‐breast cancer risk allele as the referent) and 95% confidence intervals between TDLU measures and each SNP. All statistical tests were two‐sided; P < 0.05 was considered statistically significant. Overall, 36 SNPs (58.1%) were related to higher TDLU counts although this was not statistically significant (p = 0.25). Six of the 62 SNPs (9.7%) were nominally associated with at least one TDLU measure: rs616488 (PEX14), rs11242675 (FOXQ1) and rs6001930 (MKL1) were associated with higher TDLU count (p = 0.047, 0.045 and 0.031, respectively); rs1353747 (PDE4D) and rs6472903 (8q21.11) were associated with higher acini count per TDLU (p = 0.007 and 0.027, respectively); and rs1353747 (PDE4D) and rs204247 (RANBP9) were associated with the product of TDLU and acini counts (p = 0.024 and 0.017, respectively). Our findings suggest breast cancer SNPs may not strongly influence TDLU involution. Agnostic genome‐wide association studies of TDLU involution may provide new insights on its biologic underpinnings and breast cancer susceptibility.


Journal of The American College of Radiology | 2017

Challenges With Identifying Indication for Examination in Breast Imaging as a Key Clinical Attribute in Practice, Research, and Policy

Julie Weiss; Martha Goodrich; Kimberly Harris; Rachael E. Chicoine; Marie Synnestvedt; Steve J. Pyle; Jane S. Chen; Sally D. Herschorn; Elisabeth F. Beaber; Jennifer S. Haas; Anna N. A. Tosteson; Tracy Onega

PURPOSE To assess indication for examination for four breast imaging modalities and describe the complexity and heterogeneity of data sources and ascertainment methods. METHODS Indication was evaluated among the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) breast cancer research centers (PRCs). Indication data were reported overall and separately for four breast imaging modalities: digital mammography (DM), digital breast tomosynthesis (DBT), ultrasound (US), and magnetic resonance imaging (MRI). RESULTS The breast PRCs contributed 236,262 women with 607,735 breast imaging records from 31 radiology facilities. We found a high degree of heterogeneity for indication within and across six data sources. Structured codes within a data source were used most often to identify indication for mammography (59% DM, 85% DBT) and text analytics for US (45%) and MRI (44%). Indication could not be identified for 17% of US and 26% of MRI compared with 2% of mammography examinations (1% DM, 3% DBT). CONCLUSIONS Multiple and diverse data sources, heterogeneity of ascertainment methods, and nonstandardization of codes within and across data systems for determining indication were found. Consideration of data sources and standardized methodology for determining indication is needed to assure accurate measurement of cancer screening rates and performance in clinical practice and research.


Cancer Research | 2015

Abstract 2768: Relationships between mammographic density, microvessel density, and breast biopsy diagnosis

Ashley S. Felix; Petra Lenz; Ruth M. Pfeiffer; Stephen M. Hewitt; Jennifer Morris; Deesha A. Patel; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; John A. Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Sally D. Herschorn; Jason M. Johnson; Louise A. Brinton; Mark E. Sherman; Gretchen L. Gierach

Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Introduction: Mammographic density (MD) is a strong breast cancer risk factor; however, the majority of women with high MD have neither a prevalent tumor nor will they develop one in immediate follow-up. Magnetic resonance imaging (MRI) studies suggest that background parenchymal enhancement, an indicator of vascularity, is another strong breast cancer risk predictor. However, it is uncertain how correlated microvessel density (MVD), a histological marker of vascularity, is with MD and if it adds information for disease detection. We therefore investigated relationships between MVD, area and volume measures of MD, and biopsy diagnosis among 218 women referred for image-guided vacuum-assisted breast biopsies. Methods: MVD was determined by counting CD31 (endothelial marker) positive vessels in whole sections of breast biopsies in three areas containing five 40X high power fields. Average MVD per area was calculated and then transformed based on a Box-Cox analysis to approximate a normal distribution. MD volume was quantified using single X-ray absorptiometry (SXA) in digital mammograms and MD area was quantified on the same image using thresholding methods. We used linear regression to evaluate associations between MVD (as the outcome) and MD measures (area and volume) adjusted for age and body mass index (BMI) in the overall population and stratified by biopsy diagnosis: cases (in situ or invasive carcinoma, n = 44) vs. non-cases (non-proliferative or proliferative benign breast disease, n = 174). Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MVD and biopsy diagnosis (cases vs. non-cases) in models adjusted for age, BMI, and MD measures. Results: MVD was inversely associated with absolute dense area and absolute dense volume in the overall sample (area p = 0.01, volume p = 0.11) and among non-cases (area p = 0.009, volume p = 0.007). In age-, BMI-, and dense area- or dense volume- adjusted logistic regression models, MVD was significantly associated with risk of in situ/invasive disease independent of absolute dense area (OR = 1.16, 95% CI = 1.04, 1.28) and independent of absolute dense volume (OR = 1.16, 95% CI = 1.05-1.29). Conclusion: Our histopathologic analysis suggests that tissue vascularity, as reflected by MVD, may predict breast cancer risk independently of MD, thus providing theoretical support for the potential utility in breast cancer detection of imaging methods that reflect vascularity, such as contrast-enhanced MRI. Citation Format: Ashley S. Felix, Petra Lenz, Ruth M. Pfeiffer, Stephen M. Hewitt, Jennifer Morris, Deesha Patel, Berta Geller, Pamela M. Vacek, Donald L. Weaver, Rachael E. Chicoine, John Shepherd, Amir P. Mahmoudzadeh, Jeff Wang, Bo Fan, Sally Herschorn, Jason Johnson, Louise A. Brinton, Mark E. Sherman, Gretchen L. Gierach. Relationships between mammographic density, microvessel density, and breast biopsy diagnosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2768. doi:10.1158/1538-7445.AM2015-2768


Hormones and Cancer | 2016

Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy

Hannah Oh; Zeina G. Khodr; Mark E. Sherman; Maya Palakal; Ruth M. Pfeiffer; Laura Linville; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; Roni T. Falk; Hisani N. Horne; Daphne Papathomas; Deesha A. Patel; Jackie Xiang; Xia Xu; Timothy D. Veenstra; Stephen M. Hewitt; John A. Shepherd; Louise A. Brinton; Jonine D. Figueroa; Gretchen L. Gierach


Breast Cancer Research and Treatment | 2016

Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue

Hannah Oh; Clara Bodelon; Maya Palakal; Nilanjan Chatterjee; Mark E. Sherman; Laura Linville; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; Daphne Papathomas; Deesha A. Patel; Jackie Xiang; Susan E. Clare; Daniel W. Visscher; Carolyn Mies; Stephen M. Hewitt; Louise A. Brinton; Anna Maria Storniolo; Chunyan He; Montserrat Garcia-Closas; Stephen J. Chanock; Gretchen L. Gierach; Jonine D. Figueroa


Breast Cancer Research | 2016

Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis

Ashley S. Felix; Petra Lenz; Ruth M. Pfeiffer; Stephen M. Hewitt; Jennifer Morris; Deesha A. Patel; Berta M. Geller; Pamela M. Vacek; Donald L. Weaver; Rachael E. Chicoine; John A. Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Serghei Malkov; Sally D. Herschorn; Jason M. Johnson; Renata Cora; Louise A. Brinton; Mark E. Sherman; Gretchen L. Gierach

Collaboration


Dive into the Rachael E. Chicoine's collaboration.

Top Co-Authors

Avatar

Deesha A. Patel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gretchen L. Gierach

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Louise A. Brinton

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mark E. Sherman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ruth M. Pfeiffer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge